Print

Click here to view Assets and Liabilities Statement for the Half year ended September 30, 2010

Orchid Chemicals & Pharmaceuticals Ltd.
Unaudited Financial Results for the Quarter/Half year ended September 30, 2010
(Rs.Lakhs)
   
Unaudited
Unaudited
Audited
S.No
Particulars
Three months ended
30-Sep-10
Three months ended
30-Sep-09
Six months ended
30-Sep-10
Six months ended
30-Sep-09
Year ended
31-Mar-10
1
 Net Sales
36,832.34
30,484.59
67,182.34
61,066.48
120,518.59
2
 Other Operating Income
1,347.38
956.80
4,090.22
1,257.97
4,585.61
3
 Total Operating Income (1+2)
38,179.72
31,441.39
71,272.56
62,324.45
125,104.20
4
Expenditure
a) Decrease/(Increase) in Stock in trade
(5,263.25)
1,993.05
(7,455.68)
(684.94)
26,945.14
b) Material Cost
21,239.08
8,716.18
37,463.60
21,425.04
47,207.23
c) Purchase of Traded Goods
1,213.06
835.66
2,174.42
1,706.72
3,373.83
d) Employees Cost
3,234.38
2,999.79
6,267.23
5,896.01
15,929.17
e) Depreciation / Amortisation
3,117.83
3,887.15
6,343.86
7,619.71
15,110.40
f) Other Expenditure
9,978.40
8,046.44
16,667.13
18,639.62
48,763.98
g) Total
33,519.50
26,478.27
61,460.56
54,602.16
157,329.75
5
Profit from Operations before Other Income, Interest & Exceptional Item (3-4)
4,660.22
4,963.12
9,812.00
7,722.29
(32,225.55)
6
Other Income
264.11
0.93
264.11
1.39
7.41
7
Profit/(Loss) before Interest & Exceptional Item (5+6)
4,924.33
4,964.05
10,076.11
7,723.68
(32,218.14)
8
 Interest and Finance Charges
2,511.21
5,661.53
4,782.49
10,827.83
24,123.31
9
 Profit/(Loss) after interest but before Exceptional Item (7-8)
2,413.12
(697.48)
5,293.62
(3,104.15)
(56,341.45)
10
 Exceptional Item - Gain/(Loss)
382.20
(460.41)
(87.66)
(823.95)
816.55
11
 Profit/(Loss) before Tax (9+10)
2,795.32
(1,157.89)
5,205.96
(3,928.10)
(55,524.90)
12
 Tax expenses    
   
 - Current Tax & Deferred Tax
393.83
162.28
642.99
368.12
-
13
 Net Profit/(Loss) after Tax (11-12)
2,401.49
(1,320.17)
4,562.97
(4,296.22)
(55,524.90)
14
Extraordinary Item (net of tax of Rs.12,871.42 lakhs)
-
-
-
-
88,658.86
15
Net Profit/(Loss) for the period / year
2,401.49
(1,320.17)
4,562.97
(4,296.22)
33,133.96
16
 Paid- up Equity Share Capital (Face value of Rs. 10 each)
7,044.21
7,044.21
7,044.21
7,044.21
7,044.21
17
 Reserves excluding Revaluation Reserves
-
-
-
-
90,919.30
18
 Earnings per Share (EPS) before Extraordinary Item    
   
 
- Basic Rs.
3.41*
(1.87)*
6.48*
(6.10)*
(78.82)
 
- Diluted Rs.
2.71*
(1.87)*
5.16*
(6.10)*
(78.82)
19
 Earnings per share (EPS) after Extraordinary Item    
   
 
- Basic Rs.
3.41*
(1.87)*
6.48*
(6.10)*
47.04
 
- Diluted Rs.
2.71*
(1.87)*
5.16*
(6.10)*
37.31
20
Aggregate of Public Shareholding
    
   
 

- Number of equity shares
48,696,460
55,525,904
48,696,460
55,525,904
52,128,460
  - Percentage of Shareholding
69.13
78.82
69.13
78.82
74.00
21
 Promoters and Promoter group shareholding          
  a. Pledged / Encumbered          
  - Number of shares
15,122,883
4,158,000
15,122,883
4,158,000
15,123,760
  - Percentage of shares (as a % of the total shareholding of promoter and promoter group)
69.54
27.88
69.54
27.88
82.58
  - Percentage of shares (as a % of the total share capital of company)
21.47
5.90
21.47
5.90
21.47
  b. Non - Encumbered    
   
  - Number of shares
6,622,733
10,758,172
6,622,733
10,758,172
3,189,856
  - Percentage of shares (as a % of the total shareholding of promoter and promoter group)
30.46
72.12
30.46
72.12
17.42
  - Percentage of shares (as a % of the total share capital of company)
9.40
15.28
9.40
15.28
4.53
             
* EPS is for the period (not annualised)
  • The above unaudited financial results were approved by the Board of Directors at its meeting held on Thursday, October 28, 2010 and have been subjected to limited review by the Statutory Auditors.
  • The Company is operating in single segment (i.e) "Pharmaceuticals".
  • During the quarter, the Company formed a new subsidiary namely Orchid Pharma, Inc, in the USA and acquired US based marketing Company Karalex Pharma, LLC., through the said subsidiary.
  • During the quarter under review, Diakron Pharmaceuticals Inc, USA has become a subsidiary due to further acquisition of shares.
  • The Company has exercised the option provided under the Companies (Accounting Standards) Amendment Rules, 2006 dated 31st March, 2009 in respect of AS 11. The amount remaining to be amortized in the financial statements as on September 30, 2010 on account of exercising the above option is Rs.(1556.05) lakhs (previous period Rs. 2649.55 lakhs).
  • Exceptional items represents exchange gain / (loss) on FCCBs.
  • The Company received 10 complaints during the quarter ended 30th September, 2010 from the shareholders and no complaints were pending as on 30th September, 2010.
  • The Current period figures do not reflect the sales relating to generic injectable formulation business transferred to Hospira Healthcare India Pvt. Ltd., on March 30, 2010.
  • Previous period figures have been regrouped wherever necessary.

Place : Chennai
Date : October 28, 2010

For and on behalf of the Board

K.Raghavendra Rao
Managing Director